*Indications for Use: MiSight 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.

** Compared with a single vision one-day lens over a three-year period.

1. CVI data on file, 2022. Net Plastic Neutrality, in the contact lens industry, out of the top 4 global contact lens manufacturers. Net plastic neutrality is established by purchasing credits from Plastic Bank. A credit represents the collection and conversion of one kilogram of plastic that may reach or be destined for waterways; collection locations are determined by Plastic Bank. CooperVision purchases credits equal to the weight of plastic in clariti® 1 day and MyDay® US orders in a specified time period. clariti® 1 day and MyDay® plastic is determined by the weight of plastic in the blister, the lens, and the secondary package, including laminates, adhesives, and auxiliary inputs (e.g. ink). 2 clariti® 1 day / MyDay® daily disposable orders includes [clariti® 1 day sphere, clariti® 1 day toric, and clariti® 1 day multifocal/ MyDay® daily disposable, MyDay® daily disposable toric, MyDay® daily disposable multifocal] product sold and distributed by CooperVision in the US. Net plastic neutrality is established by purchasing credits from Plastic Bank. A credit represents the collection and conversion of one kilogram of plastic that may reach or be destined for waterways. CooperVision purchases credits equal to the weight of plastic in clariti® 1 day / MyDay® daily disposable orders in a specified time period. clariti® 1 day / MyDay® daily disposable plastic is determined by the weight of plastic in the blister, the lens, and the secondary package, including laminates, adhesives, and auxiliary inputs (e.g. ink). CVI Data on file, 2022.

2. Chamberlain P, et al. A 3-year randomized clinical trial of MiSight® lenses for myopia control. Optom Vis Sci. 2019;96(8):556–567.